Integrated Filing — IndAS

General information about company
Scrip Code	523261
NSE Symbol	VENKEYS
MSEI Symbol	NOTLISTED
ISIN	INE398A01010
Name of company	Venky's (India) Limited
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-Apr-2024
Date of end of financial year	31-Mar-2025
Date of board meeting when results were approved	12-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	25-Apr-2025
Description of presentation currency	INR (in Actuals)
Reporting Type	Quarterly
Reporting Quarter	Fourth quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Multi segment
Description of single segment
Start date and time of board meeting	12-May-2025   10:30:00
End date and time of board meeting	12-May-2025   12:30:00
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes
Latest Date on which RPT policy is updated	2024-05-10
Indicate Company website link for updated RPT policy of the Company	www.venkys.com
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No
No default on loans occured.

Financial Results Ind-AS
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1	Income
	Revenue from operations	8431600000	33069900000
	Other income	118800000	441800000
	Total income	8550400000	33511700000
2	Expenses
(a)	Cost of materials consumed	5677200000	21849600000
(b)	Purchases of stock-in-trade	626300000	2268600000
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	20200000	-200400000
(d)	Employee benefit expense	745500000	2900500000
(e)	Finance costs	42800000	163400000
(f)	Depreciation, depletion and amortisation expense	99800000	367300000
(f)	Other Expenses
1	Purchase of bearer biological assets	118600000	516200000
2	Other Expenses	990100000	4019400000
	Total other expenses	1108700000	4535600000
	Total expenses	8320500000	31884600000
3	Total profit before exceptional items and tax	229900000	1627100000
4	Exceptional items	0	0
5	Total profit before tax	229900000	1627100000
6	Tax expense
7	Current tax	48800000	395000000
8	Deferred tax	48100000	65900000
9	Total tax expenses	96900000	460900000
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	133000000	1166200000
12	Profit (loss) from discontinued operations before tax	-19000000	-19000000
13	Tax expense of discontinued operations	-4800000	-4800000
14	Net profit (loss) from discontinued operation after tax	-14200000	-14200000
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	Total profit (loss) for period	118800000	1152000000
17	Other comprehensive income net of taxes	0	0
18	Total Comprehensive Income for the period	118800000	1152000000
19	Total profit or loss, attributable to
	Profit or loss, attributable to owners of parent
	Total profit or loss, attributable to non-controlling interests
20	Total Comprehensive income for the period attributable to
	Comprehensive income for the period attributable to owners of parent
	Total comprehensive income for the period attributable to owners of parent non-controlling interests
21	Details of equity share capital
	Paid-up equity share capital	140900000	140900000
	Face value of equity share capital	10	10
27	Details of debt securities
22	Reserves excluding revaluation reserve		0
23	Earnings per share
i	Earnings per equity share for continuing operations
	Basic earnings (loss) per share from continuing operations	9.44	82.78
	Diluted earnings (loss) per share from continuing operations	9.44	82.78
ii	Earnings per equity share for discontinued operations
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share
	Basic earnings (loss) per share from continuing and discontinued operations	9.44	82.78
	Diluted earnings (loss) per share from continuing and discontinued operations	9.44	82.78
24	Debt equity ratio
25	Debt service coverage ratio
26	Interest service coverage ratio
27	Disclosure of notes on financial results

Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio

Statement of Asset and Liabilities
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-Apr-2024
Date of end of reporting period		31-Mar-2025
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
	Assets
1	Non-current assets
	Property, plant and equipment	6308600000
	Capital work-in-progress	78900000
	Investment property
	Goodwill	101000000
	Other intangible assets	300000
	Intangible assets under development
	Biological assets other than bearer plants	2111100000
	Investments accounted for using equity method
	Non-current financial assets
	Non-current investments	0
	Trade receivables, non-current
	Loans, non-current	0
	Other non-current financial assets	473200000
	Total non-current financial assets	473200000
	Deferred tax assets (net)	52200000
	Other non-current assets	264000000
	Total non-current assets	9389300000
2	Current assets
	Inventories	2478800000
	Current financial asset
	Current investments	1215700000
	Trade receivables, current	5538100000
	Cash and cash equivalents	167500000
	Bank balance other than cash and cash equivalents	1719000000
	Loans, current	94100000
	Other current financial assets
	Total current financial assets	8734400000
	Current tax assets (net)
	Other current assets	100900000
	Total current assets	11314100000
3	Non-current assets classified as held for sale
4	Regulatory deferral account debit balances and related deferred tax Assets
	Total assets	20703400000
	Equity and liabilities
1	Equity
	Equity attributable to owners of parent
	Equity share capital	140900000
	Other equity	14614900000
	Total equity attributable to owners of parent	14755800000
	Non controlling interest
	Total equity	14755800000
2	Liabilities
	Non-current liabilities
	Non-current financial liabilities
	Borrowings, non-current	0
	Trade payables, non-current
	(A) Total outstanding dues of micro enterprises and small enterprises
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
	Total Trade payable
	Other non-current financial liabilities	36200000
	Total non-current financial liabilities	36200000
	Provisions, non-current	205900000
	Deferred tax liabilities (net)	395000000
	Deferred government grants, Non-current
	Other non-current liabilities	5100000
	Total non-current liabilities	642200000
	Current liabilities
	Current financial liabilities
	Borrowings, current	1651400000
	Trade payables, current
	(A) Total outstanding dues of micro enterprises and small enterprises	314500000
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	2598000000
	Total Trade payable	2912500000
	Other current financial liabilities	104800000
	Total current financial liabilities	4668700000
	Other current liabilities	512100000
	Provisions, current	40300000
	Current tax liabilities (Net)	84300000
	Deferred government grants, Current
	Total current liabilities	5305400000
3	Liabilities directly associated with assets in disposal group classified as held for sale
4	Regulatory deferral account credit balances and related deferred tax liability
	Total liabilities	5947600000
	Total equity and liabilites	20703400000
	Disclosure of notes on assets and liabilities

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-Jan-2025	01-Apr-2024
Date of end of reporting period		31-Mar-2025	31-Mar-2025
Whether accounts are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
1	Segment Revenue (Income)
	(net sale/income from each segment should be disclosed)
1	Poultry and Poultry Prodcts	4712400000	19279600000
2	Animal Health Products	875000000	3393100000
3	Oilseeds	3074100000	11407500000
	Total Segment Revenue	8661500000	34080200000
	Less: Inter segment revenue
	Revenue from operations	8661500000	34080200000
2	Segment Result
	Profit (+) / Loss (-) before tax and interest from each segment
1	Poultry and Poultry Prodcts	41200000	995100000
2	Animal Health Products	177700000	723500000
3	Oilseeds	57400000	191400000
	Total Profit before tax	276300000	1910000000
	i. Finance cost	42800000	42800000
	ii. Other Unallocable Expenditure net off Unallocable income	3600000	3600000
	Profit before tax	229900000	1627100000
3	(Segment Asset - Segment Liabilities)
	Segment Asset
1	Poultry and Poultry Prodcts	8236600000	8236600000
2	Animal Health Products	2428800000	2428800000
3	Oilseeds	6787600000	6787600000
	Total Segment Asset	17453000000	17453000000
	Un-allocable Assets	3250400000	3250400000
	Net Segment Asset	20703400000	20703400000
4	Segment Liabilities
	Segment Liabilities
1	Poultry and Poultry Prodcts	2691200000	2691200000
2	Animal Health Products	485000000	485000000
3	Oilseeds	528000000	528000000
	Total Segment Liabilities	3704200000	3704200000
	Un-allocable Liabilities	2243400000	2243400000
	Net Segment Liabilities	5947600000	5947600000
	Disclosure of notes on segments

Other Comprehensive Income
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]
1	Amount of items that will not be reclassified to profit and loss
	Total Amount of items that will not be reclassified to profit and loss
2	Income tax relating to items that will not be reclassified to profit or loss
3	Amount of items that will be reclassified to profit and loss
	Total Amount of items that will be reclassified to profit and loss
4	Income tax relating to items that will be reclassified to profit or loss
5	Total Other comprehensive income

Cash flow statement, indirect
Particulars				Year ended (dd-mm-yyyy)
A	Date of start of reporting period			2024-04-01
B	Date of end of reporting period			2025-03-31
C	Whether results are audited or unaudited			Audited
D	Nature of report standalone or consolidated			Standalone
Part I	Blue color marked fields are non-mandatory.
	Statement of cash flows
	Cash flows from used in operating activities
	Profit before tax			1627100000
	Adjustments for reconcile profit (loss)
	Adjustments for finance costs			163400000
	Adjustments for decrease (increase) in inventories			-776586000
	Adjustments for decrease (increase) in trade receivables, current			1404880000
	Adjustments for decrease (increase) in trade receivables, non-current			0
	Adjustments for decrease (increase) in other current assets			0
	Adjustments for decrease (increase) in other non-current assets			1980000
	Adjustments for other financial assets, non-current			0
	Adjustments for other financial assets, current			-42897000
	Adjustments for other bank balances			0
	Adjustments for increase (decrease) in trade payables, current			-1407293000
	Adjustments for increase (decrease) in trade payables, non-current			0
	Adjustments for increase (decrease) in other current liabilities			0
	Adjustments for increase (decrease) in other non-current liabilities			-490000
	Adjustments for depreciation and amortisation expense			367242000
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss			0
	Adjustments for provisions, current			-21625000
	Adjustments for provisions, non-current			27428000
	Adjustments for other financial liabilities, current			0
	Adjustments for other financial liabilities, non-current			0
	Adjustments for unrealised foreign exchange losses gains			-6745000
	Adjustments for dividend income			0
	Adjustments for interest income			139870000
	Adjustments for share-based payments			0
	Adjustments for fair value losses (gains)			-170272000
	Adjustments for undistributed profits of associates			0
	Other adjustments for which cash effects are investing or financing cash flow			0
	Other adjustments to reconcile profit (loss)			0
	Other adjustments for non-cash items			-582000
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships			0
	Total adjustments for reconcile profit (loss)			-601430000
	Net cash flows from (used in) operations			1025670000
	Dividends received			0
	Interest paid			0
	Interest received			0
	Income taxes paid (refund)			362437000
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) operating activities			663233000
	Cash flows from used in investing activities
	Cash flows from losing control of subsidiaries or other businesses			0
	Cash flows used in obtaining control of subsidiaries or other businesses			0
	Other cash receipts from sales of equity or debt instruments of other entities			0
	Other cash payments to acquire equity or debt instruments of other entities			0
	Other cash receipts from sales of interests in joint ventures			0
	Other cash payments to acquire interests in joint ventures			0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships			0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships			0
	Proceeds from sales of property, plant and equipment			7115000
	Purchase of property, plant and equipment			458267000
	Proceeds from sales of investment property			-76839000
	Purchase of investment property			0
	Proceeds from sales of intangible assets			0
	Purchase of intangible assets			0
	Proceeds from sales of intangible assets under development			0
	Purchase of intangible assets under development			0
	Proceeds from sales of goodwill			0
	Purchase of goodwill			0
	Proceeds from biological assets other than bearer plants			0
	Purchase of biological assets other than bearer plants			0
	Proceeds from government grants			0
	Proceeds from sales of other long-term assets			0
	Purchase of other long-term assets			0
	Cash advances and loans made to other parties			0
	Cash receipts from repayment of advances and loans made to other parties			0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts			0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts			0
	Dividends received			0
	Interest received			145271000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) investing activities	-382720000
	Cash flows from used in financing activities
	Proceeds from changes in ownership interests in subsidiaries			0
	Payments from changes in ownership interests in subsidiaries			0
	Proceeds from issuing shares			0
	Proceeds from issuing other equity instruments			0
	Payments to acquire or redeem entity's shares			0
	Payments of other equity instruments			0
	Proceeds from exercise of stock options			0
	Proceeds from issuing debentures notes bonds etc			0
	Proceeds from borrowings			0
	Repayments of borrowings			23736000
	Payments of lease liabilities			24158000
	Dividends paid			97279000
	Interest paid			156203000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) financing activities			-301376000
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes			-20863000
	Effect of exchange rate changes on cash and cash equivalents
	Effect of exchange rate changes on cash and cash equivalents			0
	Net increase (decrease) in cash and cash equivalents			-20863000
	Cash and cash equivalents cash flow statement at beginning of period			188276000
	Cash and cash equivalents cash flow statement at end of period			167413000